True Wealth Design’s Enanta Pharmaceuticals ENTA Stock Holding History

True Wealth Design’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$8.01K	Sell	608 -37	-6%	-$491	﹤0.01%	1165
2026 Q2	$9.4K	Hold	645	–	–	﹤0.01%	1080
2026 Q1	$8.15K	Hold	645	–	–	﹤0.01%	1042
2025 Q4	$10.2K	Hold	645	–	–	﹤0.01%	856
2025 Q3	$7.72K	Sell	645 -31	-5%	-$248	﹤0.01%	930
2025 Q2	$5.11K	Buy	676 +325	+93%	+$1.96K	﹤0.01%	796
2025 Q1	$1.94K	Buy	+351	New	+$2.17K	﹤0.01%	1018

Other funds holding ENTA

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

True Wealth Design's ENTA Position: Q3 2026 in Review

True Wealth Design reduced its Enanta Pharmaceuticals (ENTA) stake by 5.7% in Q3 2026, selling an estimated $491 and leaving 608 shares worth $8.01K. The position accounts for ﹤0.01% of the portfolio, ranked #1165.

True Wealth Design first reported a position in ENTA in Q1 2025 and has held it in 7 quarters since. The position peaked at $10.2K in Q4 2025. 9 funds tracked by Wall St. Rank hold ENTA as of Q3 2026.

True Wealth Design held 608 shares of Enanta Pharmaceuticals worth $8.01K as of Q3 2026.
True Wealth Design sold 37 Enanta Pharmaceuticals shares in Q3 2026, an estimated $491.
Enanta Pharmaceuticals made up ﹤0.01% of True Wealth Design's portfolio in Q3 2026, its #1165 holding.
True Wealth Design first reported a position in Enanta Pharmaceuticals in Q1 2025 and has held it in 7 quarters since.
True Wealth Design's Enanta Pharmaceuticals position peaked at $10.2K in Q4 2025.
9 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.